Acorai funding news – Helsingborg-based Acorai has Raised $4.5M Fresh Round Funding

Funding Utilisation

The capital will be used to complete it's clinical studies and prepare for regulatory submissions in the US and Europe.

Patient enrollment for it’s flagship clinical study, the CAPTURE-HF study, has been completed successfully, with over 1600 patients across 20 hospitals and 6 countries.

With its FDA Breakthrough Device Designation in place and working closely with the FDA through the TAP Pilot, Acorai targets regulatory submissions and commercial launch by 2026.

Read also - Taito.ai funding news - Helsinki-based Taito.ai has Secured €2.5 Million in Seed Funding

With an additional $6M provisioned from the EIC Fund for future equity financing, It is preparing to raise additional capital in 2025 to fund further clinical validation, regulatory approvals and early commercialisation.

Acorai CEO Filip Peters commented, “We are happy to welcome the EIC Fund as an investor in Acorai and look forward to working closely with the fund as one of Europe’s leading deep tech investors. Acorai is at a transformative point and has built a solid foundation to become a world leader in non-invasive cardiac care. With more than $6M in additional capital provisioned from the EIC Fund to Acorai’s future funding rounds, this investment will allow Acorai to scale up its clinical and regulatory efforts to reach the market. This represents another important step toward bringing our solution to the market, with the potential to impact over 60 million heart failure patients worldwide positively.”

About Acorai

Acorai is transforming non-invasive cardiac care and is dedicated to improving patient outcomes and empowering clinicians with next-generation technology for enhanced patient management.